

Submission No.	Presentation	Title	Oral/Poster	Session Title	Date	Time
ide001	O-12	Interim biomarker analysis from a randomized, double-blind, placebo-controlled, Phase 2 trial of siveprelimab (VIS649) in participants with immunoglobulin A nephropathy	Oral session 3	Biomarkers	28-Sep	14:35-15:35
ide003	O-17	Possible mediation of tonsils to IgA nephropathy caused by cnm-positive Streptococcus mutans, a major pathogen of dental caries	Oral session 4	Microbiome and Immunology	28-Sep	15:50-16:50
ide005	P-63	Clinicopathological characteristics of the pediatric IgA nephropathy with eGFR	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide006	O-23	Machine Learning in Predicting T score in the Oxford Classification System of IgA Nephropathy	Oral session 5	Pathology and Complement	30-Sep	8:30-9:30
ide007	P-54	Clinical and pathological characteristics in elderly patients with IgA nephropathy	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide008	P-03	Exploration of the molecular mechanism of hydroxychloroquine in the treatment of IgA nephropathy based on network pharmacology and molecular dynamics simulation	Poster session	Pathogenesis 1	29-Sep	11:20-12:35
ide009	P-60	Higher colocalization of IgA and complement C3 in the glomerular immunodeposits of patients with IgA nephropathy is associated with worse histopathologic findings	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide010	O-07	Clinical application of polygenic risk score in IgA nephropathy	Oral session 2	Genetics and Epigenetics	28-Sep	13:35-14:35
ide011	P-44	Impact of obesity on prognosis of IgA nephropathy separately analyzed by renal function and sex.	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide012	P-20	Relation between Porphyromonas gingivalis infection in oral cavity and elevated galactose-deficient IgA1 in IgA nephropathy	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide013	P-18	Colocalization of IgG and IgA Heavy and Light Chains in Glomerular Deposits of IgA Nephropathy Using High-Resolution Confocal Microscopy: Correlation with MEST-C Scores	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide014	O-16	CARD9 Risk Locus for IgA Nephropathy Regulates Mucosal IgA Production	Oral session 4	Microbiome and Immunology	28-Sep	15:50-16:50
ide015	P-14	Characterization of pathogenic circulating immune complexes in patients with progressive versus non-progressive IgA nephropathy	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide016	P-43	Impact of non-immune factors on renal prognosis in adult IgA Vasculitis with Nephritis : A Long-Term Retrospective Cohort Study	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide017	P-65	Progression of IgA Nephropathy is associated with mesangial C3 deposition but not disease-susceptible variant in CFH	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide018	P-73	Intensive Blood Pressure Control on the Progression of IgA Nephropathy: A Cohort Study using Marginal Structural Models	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide019	O-04	Galactose deficiency alters the structure of IgA1 and mediates IgA1 deposition in the mesangium of patients with IgA nephropathy	Oral session 1	Molecular Pathogenesis	28-Sep	11:00-12:00
ide020	P-02	Nucleotide-sensing TLR9/TLR7: therapeutic candidate for IgA nephropathy	Poster session	Pathogenesis 1	29-Sep	11:20-12:35
ide021	P-68	The Effect of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide022	P-25	Genome-wide DNA methylation association study identify DNA methylation associated with end stage renal disease	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide023	P-07	Interaction of isolated IgA1-containing circulating immune complexes with cultured primary human mesangial cells via integrin β 1	Poster session	Pathogenesis 1	29-Sep	11:20-12:35
ide024	O-08	Genome-wide association analysis of protein coding variants in IgA nephropathy	Oral session 2	Genetics and Epigenetics	28-Sep	13:35-14:35
ide025	O-20	Systematic microbiome and metabolome dysbiosis are associated with IgA nephropathy	Oral session 4	Microbiome and Immunology	28-Sep	15:50-16:50
ide026	P-05	A human origin anti-GdIgA1 antibody and its implications in IgAN	Poster session	Pathogenesis 1	29-Sep	11:20-12:35

Submission No.	Presentation	Title	Oral/Poster	Session Title	Date	Time
ide028	P-28	Comparative proteomic analysis of laser microdissected glomeruli under in IgA nephropathy	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide029	P-62	CLINICAL AND PATHOLOGICAL SPECTRUM OF PATIENTS WITH IgA NEPHROPATHY: A SINGLE CENTRE STUDY	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide030	P-22	Mixed-linkage glucans in Shen Ping decoction, traditional Chinese medicine for IgA nephropathy, inhibit cellular proliferation and signaling induced by PDGF in human mesangial cells	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide031	O-11	The amount of complement factor H-related protein-1 in serum IgA immune complexes as a novel biomarker for IgA nephropathy	Oral session 3	Biomarkers	28-Sep	14:35-15:35
ide032	P-26	Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide033	P-30	Longitudinal changes in IgA1 O- and N-glycoforms in IgA nephropathy	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide034	O-26	IgA1-Protease mRNA-LNP treatment in a mouse model expressing human IgA1 as a pre-clinical assay for IgA nephropathy	Oral session 6	Clinical Trial 1	30-Sep	9:30-10:40
ide035	P-29	Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on transcriptome analysis	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide036	O-13	Single-Cell Analyses of Blood Reveal Distinct Immune Cell Signatures of IgA nephropathy	Oral session 3	Biomarkers	28-Sep	14:35-15:35
ide037	P-59	Glomerular C3 deposition predict worse renal outcomes in Chinese patients with IgA nephropathy	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide038	O-10	GWAS uncovers novel mechanisms and potential therapeutic targets for IgA vasculitis	Oral session 2	Genetics and Epigenetics	28-Sep	13:35-14:35
ide039	O-05	Structure-Function Studies of IgG Autoantibodies in IgA Nephropathy: Defining Elements Important for Binding to Galactose-deficient IgA1	Oral session 1	Molecular Pathogenesis	28-Sep	11:00-12:00
ide040	P-08	Reverse Engineering of IgG to Enhance Binding to Galactose-deficient IgA1: An Effort to Define Interactions in IgA Nephropathy	Poster session	Pathogenesis 1	29-Sep	11:20-12:35
ide041	P-40	High Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Indicate Poor Renal Survival in Patients with IgA Nephropathy	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide042	O-06	Complement CFH genetics impacts renal survival in IgA nephropathy	Oral session 2	Genetics and Epigenetics	28-Sep	13:35-14:35
ide044	P-41	Prognostic Value of Cholesterol to High-Density Lipoprotein Cholesterol Ratio (Chol/HDL-C) in IgA Nephropathy Patients	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide045	P-38	The serial changes of clinical parameters after tonsillectomy and steroid pulse therapy in IgA nephropathy	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide046	P-10	Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by LCWE	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide048	P-79	Multicenter retrospective study of Telitacicept in the treatment of IgA nephropathy	Poster session	Clinical Trial 2	29-Sep	11:20-12:35
ide049	O-15	Analysis of the NeflgArd Part A study population confirms Nefecon suppresses circulating levels of BAFF, APRIL, and soluble BCMA in IgA nephropathy	Oral session 3	Biomarkers	28-Sep	14:35-15:35
ide050	P-34	Analysis of the NeflgArd Part A study population confirms Nefecon suppresses circulating levels of IgA-containing immune complexes in IgA nephropathy	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide051	P-35	Analysis of the NeflgArd Part A study population confirms that Nefecon modulates circulating levels of the chemokines CXCL5, CCL11, and CCL13 in IgA nephropathy	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide052	P-39	Basophils are activated by sera from IgA nephropathy patients	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide053	P-80	Durable proteinuria reduction over 2 years with Nefecon treatment: A secondary analysis of the full NeflgArd Phase III trial results	Poster session	Clinical Trial 2	29-Sep	11:20-12:35

Submission No.	Presentation	Title	Oral/Poster	Session Title	Date	Time
ide054	O-34	Hematuria reduction in patients with IgAN following Nefecon treatment: A secondary analysis of the full 2-year NeflgArd Phase III trial results	Oral session 7	Clinical Trial 2	30-Sep	10:55-11:55
ide055	P-81	Long-term renal benefit over 2 years with Nefecon verified: The NeflgArd Phase III full trial results	Poster session	Clinical Trial 2	29-Sep	11:20-12:35
ide056	P-36	High Serum IgA/C3 Ratio Predict Progression of IgA Nephropathy: A Retrospective Study	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide057	O-33	Nefecon treatment response in Asian and White patient populations with immunoglobulin A nephropathy: A 2-year analysis of the phase III NeflgArd trial	Oral session 7	Clinical Trial 2	30-Sep	10:55-11:55
ide058	P-64	Serologic and histologic predictors of long term renal outcome in biopsy-confirmed IgA nephropathy	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide059	P-55	Clinical Impact of SARS-CoV-2 infection on IgA Nephropathy	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide060	P-16	Galectin-3 plays a pathogenic role in the development of IgA nephropathy	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide061	O-14	Development of novel monoclonal antibody, EASON2, for IgA nephropathy	Oral session 3	Biomarkers	28-Sep	14:35-15:35
ide062	P-70	The Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Cohort Study	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide063	P-09	Cell-surface glycophenotyping of IgA1-secreting cells reveals glyco-memory and correlations with sialylation of Gd-IgA1	Poster session	Pathogenesis 1	29-Sep	11:20-12:35
ide064	P-04	LIF/LIFR/gp130/JAK2/STAT1 pathway drives overproduction of galactose-deficient IgA1 in IgA1-producing cell lines derived from tonsils of patients with IgA nephropathy	Poster session	Pathogenesis 1	29-Sep	11:20-12:35
ide065	P-17	Regulatory function of FcγRIIB involving the NLRP3 inflammasome in an experimental IgA nephropathy	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide067	O-01	Characteristics of kidney resident plasma cells in IgA nephropathy	Oral session 1	Molecular Pathogenesis	28-Sep	11:00-12:00
ide068	P-11	Tackling IgA Nephropathy with systems medicine - a personal view	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide069	P-46	Clinical renal outcomes of immunoglobulin A nephropathy associated with hepatitis B or hepatitis C virus infection	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide070	P-71	The association of 5-year therapeutic responsiveness with long-term renal outcome in IgA nephropathy	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide071	P-21	Prevalence of periodontitis-related bacteria in tonsils of IgA nephropathy patients compared with those in habitual tonsillitis patients.	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide073	P-42	Association of urinary C4d levels and CKD progression in a large IgA nephropathy cohort	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide074	P-56	Microscopic hematuria in IgA nephropathy predicts gross hematuria following COVID-19 vaccination	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide075	P-50	Diagnostic Prediction of IgA Nephropathy by Machine Learning Based on Blood and Urine Tests	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide076	P-37	Clinical significance of glomerular and circulating apoptosis inhibitor of macrophage in IgAN nephropathy	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide077	O-32	Thirty-six-week Efficacy and Safety of Ataccept 150 mg in the Randomized, Double-Blind, Placebo-Controlled Ph2b ORIGIN Study in Patients with IgAN and Persistent Proteinuria	Oral session 7	Clinical Trial 2	30-Sep	10:55-11:55
ide078	P-83	Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Povetacept (RUBY-1), a Dual BAFF/APRIL Antagonist for Treatment of Autoimmune Glomerulonephritis	Poster session	Clinical Trial 2	29-Sep	11:20-12:35
ide079	P-78	Current status of treatments for IgA nephropathy in Japan: Lessons from medical claim database	Poster session	Clinical Trial 2	29-Sep	11:20-12:35

Submission No.	Presentation	Title	Oral/Poster	Session Title	Date	Time
ide080	P-31	Elevated serum Gd-IgA1/s.IgA levels and not serum Gd-IgA1 alone is an independent risk factor for composite outcome in South Asian IgAN.	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide081	P-74	Clinical and mechanistic studies of two Chinese herbal formulations for treatment of IgA nephropathy	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide082	P-51	Work, productivity, and activity impairment in patients with immunoglobulin A nephropathy: Results from a real-world study	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide083	P-12	Adaptive remodeling of mesangial matrix proteoglycan composition during IgA nephropathy	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide084	O-24	Digital spatial profiling reveals early evidence of complement activity associated endocapillary hypercellularity in glomerular endothelial cells in IgA Nephropathy	Oral session 5	Pathology and Complement	30-Sep	8:30-9:30
ide085	P-32	Relevance of serum APRIL as a biomarker in South-Asian prospective longitudinal observational IgA nephropathy cohort (GRACE-IgANI)	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide086	P-85	Investigation of the efficacy of immunosuppressive therapy in IgA nephropathy using Δ eGFR calculated from long-term serial data.	Poster session	Clinical Trial 2	29-Sep	11:20-12:35
ide087	P-72	IGA NEPHROPATHY SPONSORED CLINICAL TRIALS IN SOUTH AMERICA AND POTENTIALITY OF THE REGION FOR GLOBAL REPRESENTATION. A FIVE-YEAR EXPERIENCE	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide088	P-45	DOES FEMALE GENDER AFFECT THE PROGNOSIS OF PATIENTS WITH IGAN AFTER KIDNEY TRANSPLANT?	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide089	P-86	Challenges and lessons learnt from industry driven multi-centre global clinical trials in IgAN - A site investigators' perspective	Poster session	Clinical Trial 2	29-Sep	11:20-12:35
ide090	P-58	Protocol and Rationale for a Multi-center, Multi-arm and Multi-stage (MAMS) Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven IgA nephropathy.	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide091	O-35	ASSIST Study Design: A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Patients with IgA Nephropathy (IgAN) on SGLT2i	Oral session 7	Clinical Trial 2	30-Sep	10:55-11:55
ide092	O-30	BEYOND: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy	Oral session 6	Clinical Trial 1	30-Sep	9:30-10:40
ide093	P-84	Updated Interim Results of a Phase 1/2 Study of Zigakibart (BION-1301) in Patients with IgA Nephropathy	Poster session	Clinical Trial 2	29-Sep	11:20-12:35
ide094	P-87	COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): an Interim Analysis	Poster session	Clinical Trial 2	29-Sep	11:20-12:35
ide095	O-31	Interim Analysis of a Global Phase 2 Randomized Clinical Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in Immunoglobulin A Nephropathy	Oral session 6	Clinical Trial 1	30-Sep	9:30-10:40
ide096	P-13	Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan is protective in the gddY mouse model of IgA nephropathy to a greater extent than losartan	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide097	P-57	Diagnostic pathways in immunoglobulin A nephropathy in Japan: Results from a real-world survey	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide098	P-53	IgA nephropathy: A real-world comparison between disease severity, symptom burden, and treatment satisfaction reported by patients and nephrologists	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide099	P-23	Characterizations of the gut virome in patients with IgA nephropathy	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide100	P-27	Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide101	O-02	APRIL is activated in children IgAN triggered by sCD89	Oral session 1	Molecular Pathogenesis	28-Sep	11:00-12:00
ide102	P-33	GalD: An available and high-performing lectin-based test for serum galactose-deficient IgA1	Poster session	Biomarkers 1	29-Sep	11:20-12:35
ide103	P-19	mTOR inhibitors reduce IgA1 deposits and glomerular inflammation in a humanized mouse IgAN model.	Poster session	Pathogenesis 2	29-Sep	11:20-12:35

Submission No.	Presentation	Title	Oral/Poster	Session Title	Date	Time
ide104	P-01	Soluble Fc receptor I (CD89) as crucial inflammatory actor in childhood IgA nephropathy	Poster session	Pathogenesis 1	29-Sep	11:20-12:35
ide105	O-18	Gut Microbiota in Immunoglobulin A Nephropathy	Oral session 4	Microbiome and Immunology	28-Sep	15:50-16:50
ide106	O-28	Utilizing machine learning for detecting patients with IgA nephropathy from a computerized medical bill database	Oral session 6	Clinical Trial 1	30-Sep	9:30-10:40
ide107	O-03	Novel IgA autoantibodies against mesangial cells, anti-βII spectrin IgA, is essential for development of IgA nephropathy	Oral session 1	Molecular Pathogenesis	28-Sep	11:00-12:00
ide108	O-21	Histologic and immunologic markers to predict renal recurrence in IgA vasculitis nephritis	Oral session 5	Pathology and Complement	30-Sep	8:30-9:30
ide109	P-48	IGA NEPHROPATHY: A 25-YEAR ARGENTINIAN SINGLE CENTER EXPERIENCE.	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide110	P-67	ARE ACTIVE CRESCENTS A RISK MARKER OF PROGRESSION IN PRIMARY IGA NEPHROPATHY? A SINGLE-CENTER 25-YEAR EXPERIENCE	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide111	O-29	Evaluation of the safety and efficacy of adipose-derived mesenchymal stem cells (ADR-001) treatment for refractory IgA nephropathy	Oral session 6	Clinical Trial 1	30-Sep	9:30-10:40
ide112	P-75	Associations of Corticosteroid Therapy and Tonsillectomy with Kidney Outcome in Patients with Advanced IgA nephropathy: A Nationwide Retrospective Cohort Study	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide113	P-61	RSV G activates the alternative pathway of complement and promotes HGECs to recruit CD16 + monocytes to participate in IgAN pathogene	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide114	P-69	The utility of proteinuria and hematuria remission criteria by the Japanese Society of Nephrology in IgA-nephropathy patients	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide115	P-52	Characteristics of patients with gross hematuria after COVID-19 mRNA vaccination: a prospective cohort study	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35
ide116	P-06	The mechanism for cell-surface expression of beta2-spectrin at mesangial region.	Poster session	Pathogenesis 1	29-Sep	11:20-12:35
ide117	P-47	Elevated inflammatory biomarkers are risk factors for composite outcome in South Asian IgAN.	Poster session	Biomarkers 2	29-Sep	11:20-12:35
ide118	P-15	Comprehensive molecular analysis of tonsillar tissues in IgA nephropathy	Poster session	Pathogenesis 2	29-Sep	11:20-12:35
ide119	P-77	Association of hematuria relapse after the remission period with intensive treatment is associated with IgA nephropathy outcomes	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide120	O-25	Circulating alternative pathway complement cleavage factor Bb is associated with vascular lesions and outcomes in IgA nephropathy	Oral session 5	Pathology and Complement	30-Sep	8:30-9:30
ide121	P-76	Association of tonsillectomy in IgA nephropathy patients with JSN remission within 2 years of follow-up	Poster session	Clinical Trial 1	29-Sep	11:20-12:35
ide122	O-27	Therapeutic effect of Hydroxychloroquine in IgA Nephropathy course (QUIgAN study)	Oral session 6	Clinical Trial 1	30-Sep	9:30-10:40
ide124	O-09	Multi-omics analysis based on Single-cell Transcriptome Sequencing and Proteomic Spectra Reveal α1-antitrypsin Effected on IgA Nephropathy	Oral session 2	Genetics and Epigenetics	28-Sep	13:35-14:35
ide125	O-22	Validation of the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy: evidence from the VALIGA cohort	Oral session 5	Pathology and Complement	30-Sep	8:30-9:30
ide126	P-66	OXFORD SCORE AND CLINICAL IMPLICATIONS IN PRIMARY IGA NEPHROPATHY. A SINGLE CENTER 25-YEAR EXPERIENCE IN ARGENTINA	Poster session	Pathology and complement	29-Sep	11:20-12:35
ide127	P-24	RNA-Seq analysis of tonsils in patients with IgA nephropathy	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
ide128	P-49	Proteinuria and disease progression in the RaDaR IgAN cohort	Poster session	Diagnosis or prediction	29-Sep	11:20-12:35

Submission No.	Presentation	Title	Oral/Poster	Session Title	Date	Time
ide129	O-19	Plasmacytoid dendritic cells are involved in the production of galactose-deficient IgA1	Oral session 4	Microbiome and Immunology	28-Sep	15:50-16:50
ide130	P-82	Comparison of the dissolution profile of Nefecon and three other commercially available oral formulations of budesonide: implications for interchangeability	Poster session	Clinical Trial 2	29-Sep	11:20-12:35
Late breaking	LB-1	Sparsentan Treatment of Incident Patients With IgA Nephropathy as First-line Therapy: Interim Findings From the SPARTAN Trial	Oral session 7	Clinical Trial 2	30-Sep	10:55-11:55
Late breaking	LB-2	Effect of corticosteroids on kidney and safety outcomes in IgA nephropathy across different levels of proteinuria and eGFR: A post hoc analysis of the TESTING study	Oral session 7	Clinical Trial 2	30-Sep	10:55-11:55
Late breaking	LB-3	New genes potentially involved in IgA nephropathy from DNA methylation analysis	Poster session	Microbiome+genetics	29-Sep	11:20-12:35
Late breaking	LB-4	Glomerular spatial transcriptomics of IgA nephropathy according to the presence of mesangial proliferation and crescent formation	Poster session	Pathology and complement	29-Sep	11:20-12:35